XML 81 R49.htm IDEA: XBRL DOCUMENT v3.8.0.1
Intangible Assets and Goodwill (Details) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2017
Jun. 30, 2017
Mar. 31, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Dec. 31, 2016
Intangible assets              
Amortization of acquired intangible assets $ 108.9     $ 99.7 $ 674.9 $ 281.4  
Total intangible assets, gross 8,295.8       8,295.8   $ 7,742.3
Accumulated Amortization (4,276.4)       (4,276.4)   (3,934.0)
Intangible assets, net 4,019.4       4,019.4   3,808.3
Payment made to Forward Pharma     $ 1,250.0        
TECFIDERA intellectual property charges             454.8
Intangible Assets and Goodwill (Textual) [Abstract]              
Accumulated impairment losses related to goodwill 0.0       0.0    
Expected future amortization expense, 2017 (remaining three months) 106.8       106.8    
Expected future amortization expense, 2018 421.3       421.3    
Expected future amortization expense, 2019 404.0       404.0    
Expected future amortization expense, 2020 389.6       389.6    
Expected future amortization expense, 2021 256.6       256.6    
Expected future amortization expense, 2022 244.7       244.7    
TECFIDERA              
Intangible assets              
Amortization of acquired intangible assets 30.4       413.4    
Increase in acquired and in-licensed rights and patents     $ 795.2        
Out-licensed patents              
Intangible assets              
Cost 543.3       543.3   543.3
Accumulated Amortization (532.7)       (532.7)   (523.6)
Net 10.6       $ 10.6   19.7
Out-licensed patents | Minimum              
Intangible assets              
Estimated life, (in years)         13 years    
Out-licensed patents | Maximum              
Intangible assets              
Estimated life, (in years)         23 years    
Developed technology              
Intangible assets              
Cost 3,005.3       $ 3,005.3   3,005.3
Accumulated Amortization (2,675.8)       (2,675.8)   (2,634.3)
Net 329.5       $ 329.5   371.0
Developed technology | Minimum              
Intangible assets              
Estimated life, (in years)         15 years    
Developed technology | Maximum              
Intangible assets              
Estimated life, (in years)         23 years    
Developed technology | AVONEX              
Intangible assets              
Net 322.5       $ 322.5    
Acquired and in-licensed rights and patents              
Intangible assets              
Cost 4,002.6       4,002.6   3,481.7
Accumulated Amortization (1,067.9)       (1,067.9)   (776.1)
Net 2,934.7       $ 2,934.7   2,705.6
Acquired and in-licensed rights and patents | Minimum              
Intangible assets              
Estimated life, (in years)         4 years    
Acquired and in-licensed rights and patents | Maximum              
Intangible assets              
Estimated life, (in years)         18 years    
Acquired and in-licensed rights and patents | SPINRAZA              
Intangible assets              
Increase in acquired and in-licensed rights and patents 40.0 $ 50.0     $ 150.0    
Acquired and in-licensed rights and patents | Samsung Biosimilar Agreement [Member]              
Intangible assets              
Increase in acquired and in-licensed rights and patents 25.0            
In Process Research and Development [Member]              
Intangible assets              
Indefinite lived intangible assets useful life         Indefinite until commercialization    
Cost and Net 680.6       $ 680.6   648.0
Accumulated Amortization 0.0       $ 0.0   0.0
Trademarks and Trade Names [Member]              
Intangible assets              
Indefinite lived intangible assets useful life         Indefinite    
Cost and Net 64.0       $ 64.0   64.0
Accumulated Amortization 0.0       0.0   $ 0.0
TYSABRI product | Acquired and in-licensed rights and patents              
Intangible assets              
Net $ 2,293.9       $ 2,293.9